论文部分内容阅读
英国学者发现,对于患有糖尿病(DM)和慢性肾脏疾病(CKD)的患者,铁剂和促红细胞生成素(ESA)补充可能在血糖控制情况不变的情况下,导致HbA_1c水平明显下降。目前,常规毛细血管血糖监测和动态血糖监测系统(CGMS)仍是这类患者监测血糖控制水平的最佳选择。该项前瞻性研究共纳入30例接受静脉注射铁剂(A组,15例)和/或ESA(B组,15例)治疗的ⅢB期或Ⅳ期CKD和T2DM患者,测定HbA_1c、每周3次测一日7点血糖和CGMS监测血糖控制情况。
British researchers found that iron supplementation and erythropoietin (ESA) supplementation could lead to a significant reduction in HbA 1c levels with unchanged blood glucose control in patients with diabetes mellitus (DM) and chronic kidney disease (CKD). At present, routine capillary blood glucose monitoring and dynamic glucose monitoring system (CGMS) is still the best choice for monitoring blood glucose levels in these patients. This prospective study enrolled 30 patients with grade ⅢB or Ⅳ CKD and T2DM treated with intravenous iron (group A, n = 15) and / or ESA (group B, n = 15). HbA_1c Test blood glucose and CGMS at 7 o’clock on the 1st to monitor glycemic control.